Table 1 Demographic, clinical, and laboratory characteristics of patients with psoriatic arthritis, rheumatoid arthritis, and controls
Characteristic | Psoriatic arthritis | Rheumatoid arthritis (group I) | Matched rheumatoid arthritis (group II) | Controls |
|---|---|---|---|---|
Number of patients | 15 | 49 | 30 | 8 |
Age (years) | 55.7 ± 10.7 | 57.6 ± 14.6 | 56.3 ± 16.3 | 38.1 ± 21.9 |
Sex (women/men)* | 8/7 | 42/7 | 20/10 | 4/4 |
Disease duration (months) | 63.5 ± 62.7 | 93.5 ± 98.7 | 78.2 ± 86.2 | NA |
Morning stiffness (minutes) | 70.4 ± 55.7 | 96.2 ± 96.3 | 76.8 ± 92.1 | NA |
Number of tender joints* | 8.0 ± 5.5 | 13.7 ± 9.4 | 9.1 ± 7.3 | 0 |
Number of swollen joints | 5.3 ± 4.4 | 8.0 ± 5.8 | 5.0 ± 3.9 | 0 |
Ritchie index | 8.3 ± 5.7 | 11.6 ± 6.9 | 7.0 ± 5.1 | 0 |
ESR (mm/h) | 34.7 ± 21.8 | 49.1 ± 31.6 | 45.5 ± 35.7 | ND |
CRP (mg/l) | 30.4 ± 39.4 | 30.3 ± 34.4 | 26.6 ± 36.1 | ND |
Number of patients with IgM rheumatoid factor** | 1 (6.7%) | 33 (67.3%) | 18 (60%) | ND |
Rate of early enhancement§ | 1.0 ± 0.6 | 1.6 ± 0.7 | 1.3 ± 0.7 | 0.1 ± 0.1 |
Relative enhancement § | 87.1 ± 39.2 | 125.8 ± 48.0 | 107.3 ± 48.2 | 15.5 ± 19.2 |